§ 07 · ABOUT
About GHK-Cu DR
An independent editorial digest of the peer-reviewed research literature on GHK-Cu — the corporate-research-brief reading of a fifty-year copper-peptide arc.
What this site is
GHK-Cu DR is an independent editorial project that publishes summaries of the peer-reviewed research literature on GHK-Cu. The site reads the corpus chronologically — from the 1973 Pickart isolation paper to the 2024 fibrosis and liposomal-permeation work — and renders it in the corporate-research-brief register: a horizontal-timeline navigation, milestone cards per study, and inline citation tooltips that link to the primary sources.
What this site is not
We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The 'DR' in the domain name is editorial framing — a position the publisher occupies relative to the literature (digest, doctor, dose-record — deliberately ambiguous in the corporate-brief register), not a claim about the site's services or staff.
Editorial methodology
Every page on the site cites the primary literature inline. Quantitative claims (doses, percentages, sample sizes, half-lives) map to a numbered citation in the study references index. The author concentration in the GHK-Cu corpus — Loren Pickart and co-authors — is acknowledged on the references page; this site cites that work alongside independent investigators (Mulder, Leyden, Miller, Pyo, Campbell, Park, He, Czyrski, Pai) to keep the reading balanced. We do not invent findings, fabricate citations, or summarize work we have not read.
What we cover
The chronological arc covered on the site: 1973 (Pickart isolation), 1994 (Mulder diabetic-ulcer trial), 2002 (Leyden photoaging cream), 2006 (Miller CO2-laser study), 2007 (Pyo dermal-papilla hair work), 2012 (Campbell COPD emphysema gene-signature), 2015 (Pickart antioxidant gene work), 2018 (Pickart and Margolina Connectivity Map update), 2022 (Park mouse COPD model), and 2024 (He fibrosis paper, Czyrski liposomal-permeation work). The five-decade record is read as an unfolding research program, not as a settled clinical doctrine.
Regulatory framing
GHK-Cu is not FDA-approved as a therapeutic drug for any human indication. Topical cosmetic use under the INCI name Copper Tripeptide-1 is permitted under cosmetic regulation. Injectable GHK-Cu sold as a 'research chemical' is for in-vitro laboratory research and is not intended for human consumption. The site's contents reflect that regulatory status: dermatological-topical evidence is treated as the primary human evidence base, and systemic / injection-form claims are framed in research-context with the gap in human pharmacokinetic data acknowledged.